Literature DB >> 29909108

Rate of Progression of Aortic Stenosis and its Impact on Outcomes in Patients With Radiation-Associated Cardiac Disease: A Matched Cohort Study.

Eoin Donnellan1, Brian P Griffin1, Douglas R Johnston2, Zoran B Popovic1, Alaa Alashi1, Samir R Kapadia1, E Murat Tuzcu1, Amar Krishnaswamy1, Stephanie Mick2, Lars G Svensson2, Milind Y Desai3.   

Abstract

OBJECTIVES: The aim of this study was to study differences in progression of aortic stenosis (AS) in patients with mediastinal radiotherapy (XRT)-associated moderate AS versus a matched cohort during the same time frame, and to ascertain need for aortic valve replacement (AVR) and longer-term survival.
BACKGROUND: Rate of progression of XRT-associated moderate AS and its impact on outcomes is not well-described.
METHODS: We included 81 patients (age 61 ± 13 years; 57% female) with at least XRT-associated moderate AS (aortic valve area [AVA] 1.05 ± 0.3 cm2; mean gradient 24 ± 10 mm Hg) who had ≥2 transthoracic echocardiograms (TTEs) 1 year apart and matched them in a 1:2 fashion on the basis of age, sex, and AVA with those without prior XRT. Serial aortic valve gradients and AVA were recorded. AVR and longer-term all-cause mortality during follow-up were recorded.
RESULTS: A total of 100% of patients had 1, a total of 71% had 2, and 39% had 3 follow-up TTEs. Before AVR, mean AVG and AVA were not significantly different between XRT and comparison groups. At 3.6 ± 2.0 years from baseline TTE, 146 (60%) underwent AVR (16% transcatheter), with significantly more patients in the XRT group undergoing AVR (80% vs. 50%; p < 0.01), at a much shorter time (2.9 ± 1.6 years vs. 4.1 ± 2.4 years; p < 0.01). At 6.6 ± 4.0 years from the initial TTE, 49 (20%) patients died, with a significantly higher mortality in the XRT group (40% vs. 11%; p < 0.01), with prior XRT associated with increased longer-term mortality, whereas AVR was associated with improved longer-term survival.
CONCLUSIONS: In patients with moderate AS, those with prior XRT have a similar rate of progression of AS versus a comparison group. A higher proportion of patients in the XRT group were referred for AVR at a shorter time from baseline TTE. Despite that, the XRT patients had significantly higher longer-term mortality, and prior exposure to XRT was associated with significantly increased longer-term mortality.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aortic stenosis; progression; radiation heart disease

Mesh:

Year:  2018        PMID: 29909108     DOI: 10.1016/j.jcmg.2018.04.019

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  5 in total

Review 1.  The Onco-cardiologist Dilemma: to Implant, to Defer, or to Avoid Transcatheter Aortic Valve Replacement in Cancer Patients with Aortic Stenosis?

Authors:  Serban Mihai Balanescu; Dinu Valentin Balanescu; Teodora Donisan; Eric H Yang; Nicolas Palaskas; Juan Lopez-Mattei; Saamir Hassan; Peter Kim; Mehmet Cilingiroglu; Konstantinos Marmagkiolis; Biswajit Kar; Cezar Iliescu
Journal:  Curr Cardiol Rep       Date:  2019-07-08       Impact factor: 2.931

2.  Rate of Progression of Aortic Stenosis in Patients With Cancer.

Authors:  Katia Bravo-Jaimes; Nicolas L Palaskas; Jose Banchs; Nadia I Abelhad; Alveena Altaf; Sushanth Gouni; Juhee Song; Saamir A Hassan; Cezar Iliescu; Anita Deswal; Syed Wamique Yusuf
Journal:  Front Cardiovasc Med       Date:  2021-03-18

Review 3.  Moderate aortic stenosis: culprit or bystander?

Authors:  Varayini Pankayatselvan; Inbar Raber; David Playford; Simon Stewart; Geoff Strange; Jordan B Strom
Journal:  Open Heart       Date:  2022-01

Review 4.  Mediastinal irradiation and valvular heart disease.

Authors:  Shivaraj Patil; Srinath-Reddi Pingle; Khalid Shalaby; Agnes S Kim
Journal:  Cardiooncology       Date:  2022-04-08

5.  Contemporary Trends and Outcomes of Percutaneous and Surgical Aortic Valve Replacement in Patients With Cancer.

Authors:  Avirup Guha; Amit K Dey; Sameer Arora; Matthew A Cavender; John P Vavalle; Joseph F Sabik; Ernesto Jimenez; Hani Jneid; Daniel Addison
Journal:  J Am Heart Assoc       Date:  2020-01-21       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.